RPRX

Royalty Pharma Plc

• Seeking Alpha·4d ago

  BeOne Medicines: Brukinsa And Tevimbra Face A High Bar

• Seeking Alpha·10/18 15:04

  Goldman's defensive stocks with quality-growth characteristics

• Seeking Alpha·10/16 16:19

  Royalty Pharma declares $0.235 dividend

• Dow Jones·10/16 12:00

  Press Release: Royalty Pharma declares fourth quarter 2026 dividend

• TipRanks·10/12 11:46

  Royalty Pharma (RPRX) Gets a Buy from Citi

• TipRanks·10/09 12:17

  Bank of America Securities Remains a Buy on Royalty Pharma (RPRX)

• NASDAQ·10/08 15:10

  Why Royalty Pharma (RPRX) is Poised to Beat Earnings Estimates Again

• Dow Jones·10/07 15:06

  Royalty Pharma Is Maintained at Overweight by Morgan Stanley

• TipRanks·10/07 12:26

  Royalty Pharma (RPRX) Gets a Buy from Morgan Stanley

• Seeking Alpha·10/03 13:34

  Revolution Medicines: Priced For A Label The Trial Didn't Test; Hold

• TipRanks·09/24 09:30

  Analysts Offer Insights on Healthcare Companies: Royalty Pharma (RPRX), Travere Therapeutics (TVTX) and Veeva Systems (VEEV)

• Seeking Alpha·09/20 18:57

  FDA, Duke-Margolis workshop to examine evidence standards for rare diseases

• TipRanks·09/09 11:00

  Wall Street Analysts Are Bullish on Top Healthcare Picks

• TipRanks·09/09 02:30

  Analysts Conflicted on These Healthcare Names: Amgen (AMGN), Beam Therapeutics (BEAM) and Royalty Pharma (RPRX)

• Dow Jones·09/08 17:26

  Royalty Pharma Down Nearly 6%, on Pace for Largest Percent Decrease Since March 2025 -- Data Talk